Liquidia Corporation (LQDA) Stock Grade

About Liquidia Corporation's fundamentals

Liquidia Corporation is a pharmaceutical company with a market capitalization of $6.6 billion that has experienced extraordinary revenue growth of 1,031.2% year-over-year, indicating rapid commercial expansion. However, the company currently operates at a significant loss, with a net margin of -43.5%, and reported a net loss in its latest annual statement, suggesting it has not yet achieved profitability despite its sales momentum. The company's low P/E ratio of 2.0 reflects its loss-making status, and it does not pay a dividend. This profile is typical of growth-stage pharmaceutical companies investing heavily in commercialization while working toward profitability.